Table 3.
Non-prescribed use of methadone, buprenorphine, and buprenorphine/naloxone in the study population
| Non-prescribed use of methadone | Non-prescribed use of buprenorphine | Non-prescribed use of buprenorphine/naloxone | |
|---|---|---|---|
| Total | |||
| Whole population (411) | 87.8% | 80.5% | 50.6% |
| Gender | |||
| Woman (104) | 85.6% | 75.0% | 54.1% |
| Man (307) | 88.6% | 82.4% | 43.0% |
| Chi-2 (P value) | 0.415 | 0.099 | 0.054 |
| Country of birth | |||
| Sweden (333) | 88.9% | 82.6% | 53.5% |
| Other country (78) | 83.3% | 71.8% | 42.1% |
| Chi-2 (P value) | 0.177 | 0.030 | 0.073 |
| Education | |||
| Comprehensive school (195) | 86.7% | 82.6% | 52.9% |
| High school or more (216) | 88.9% | 78.7% | 50.0% |
| Chi-2 (P value) | 0.491 | 0.324 | 0.563 |
| Drug | |||
| Methadone (219) | 92.7% | 74.0% | 45.1% |
| Buprenorphine (112) | 81.3% | 87.5% | 49.5% |
| Buprenorphine/naloxone (80) | 83.8% | 88.8% | 70.9% |
| Chi-2 (P value) | 0.005 | 0.002 | 0.000 |
| Treatment period, length of | |||
| Up to 1 year (138) | 90.6% | 88.4% | 65.9% |
| 1–3 years (140) | 90.7% | 85.7% | 58.6% |
| More than 3 years (130) | 82.3% | 66.2% | 25.8% |
| Chi-2 (P value) | 0.054 | 0.000 | 0.000 |
| Experience of involuntary discharge | |||
| No (262) | 85.9% | 80.2% | 52.3% |
| Yes (149) | 91.3% | 81.2% | 49.7% |
| Chi-2 (P value) | 0.108 | 0.795 | 0.606 |
| City | |||
| Malmö (196) | 92.9% | 75.5% | 51.5% |
| Göteborg (118) | 81.4% | 88.1% | 49.1% |
| Lund (54) | 88.9% | 77.8% | 46.3% |
| Jönköping/Norrköping (43) | 81.4% | 86.0% | 63.4% |
| Chi-2 (P value) | 0.012 | 0.035 | 0.366 |
| Interviewers | |||
| Researchers (280) | 88.2% | 78.6% | 49.1% |
| Privileged access interviewers (131) | 87.0% | 84.7% | 56.2% |
| Chi-2 (P value) | 0.731 | 0.142 | 0.184 |